UK markets close in 3 hours 41 minutes
  • FTSE 100

    6,636.49
    +47.96 (+0.73%)
     
  • FTSE 250

    21,255.31
    +33.85 (+0.16%)
     
  • AIM

    1,190.40
    -1.77 (-0.15%)
     
  • GBP/EUR

    1.1568
    +0.0015 (+0.13%)
     
  • GBP/USD

    1.3921
    0.0000 (-0.00%)
     
  • BTC-GBP

    35,057.49
    +574.12 (+1.66%)
     
  • CMC Crypto 200

    982.17
    -4.48 (-0.45%)
     
  • S&P 500

    3,901.82
    +90.67 (+2.38%)
     
  • DOW

    31,535.51
    +603.14 (+1.95%)
     
  • CRUDE OIL

    60.89
    +0.25 (+0.41%)
     
  • GOLD FUTURES

    1,729.60
    +6.60 (+0.38%)
     
  • NIKKEI 225

    29,408.17
    -255.33 (-0.86%)
     
  • HANG SENG

    29,095.86
    -356.71 (-1.21%)
     
  • DAX

    14,083.95
    +71.13 (+0.51%)
     
  • CAC 40

    5,828.21
    +35.42 (+0.61%)
     

Insights on the Polymerase Chain Reaction for Point-of-Care Diagnostics Global Market to 2025 - Impact Analysis of COVID-19

Research and Markets
·6-min read

Dublin, Feb. 11, 2021 (GLOBE NEWSWIRE) -- The "Polymerase Chain Reaction (PCR) for Point-of-Care (POC) Diagnostics" report has been added to ResearchAndMarkets.com's offering.

The scope of this report is broad and covers the components available in the polymerase chain reaction (PCR) for point-of-care (POC) diagnostics market and potential end-users. Revenue forecasts from 2020 to 2025 are given for types of kits and equipment, with estimated value derived from the revenues of manufacturers.

The report also includes a discussion on the major players in each regional market. Further, it explains major drivers and regional dynamics of the global market. The report concludes with a look at the vendor landscape and includes detailed profiles of major vendors in the global PCR for POC diagnostics market.

This report will cover the variety of markets being served by these newly emerging diagnostic kits, the companies that produce them, and the types of end users who are embracing these kits. This study does not cover the existing kit market for molecular diagnostics, either through manual use or through a variety of automation platforms. These kits, which enable processing of samples for PCR without further operator intervention, by definition do not require much in the way of sample preparation or consumables other than what is used to generate results, so there will not be a discussion of that marketplace. However, the appropriate consumables necessary, as well as the cyclers that are paired with these kits, will be covered as a part of this report.

The Report Includes:

  • 18 data tables and 23 additional tables

  • A comprehensive overview of the global market for polymerase chain reaction (PCR) for point-of-care (POC) diagnostics, along with future commercial potential for each key market segment

  • Analyses of the global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025

  • Estimation of the actual market size and revenue forecasts for the global PCR for POC diagnostics market and potential end-users for types of kits and equipment

  • Identification of the emerging market opportunities and future market potential of the PCR for POC diagnostics industry, technology trends and issues, market determinants, and regulatory frameworks pertaining to PCR technology

  • Competitive landscape specific to COVID-19 impact analysis, with emphasis on FDA's contribution to COVID-19 diagnostic testing and key developments within the segment

  • Patent review and new developments in POC PCR technologies, by companies or research institutes

  • Discussion of the vendor landscape and detailed profiles of major vendors in the global PCR for POC diagnostics market. Major players include Abbott Laboratories, Bio-Rad Laboratories Inc., Cepheid, Roche Diagnostics and Qiagen N.V.

Polymerase chain reaction for point-of-care diagnostics is being most rapidly deployed for two types of infectious diseases, respiratory infections and sexually transmitted diseases. Respiratory infections such as influenza and respiratory syncytial virus are common targets for point-of-care diagnostics as these tests replace existing lateral flow immunoassays due to improved precision in results. The other area of infectious disease diagnostics where such technology has had strong growth is in the area of sexually transmitted diseases. The integration of such testing with counseling and connection to resources is proving to be a popular combination for healthcare providers.

The growing prevalence of infectious diseases and the ongoing innovation in the development of diagnostics for the novel coronavirus (COVID-19) are the prime factors creating huge potential for the global market. Market players, governments and research organizations are actively looking for the development of innovative treatment and diagnosis for COVID-19 with the adoption of PCR techniques. For instance, in October 2020, Rover Diagnostics (U.S.) and Columbia Engineering (U.S.) announced the development of a new, low-cost, simple-to-use, ultrafast point-of-care test for COVID-19. It reportedly can provide reverse transcription polymerase chain reaction (RT PCR) results in just eight minutes, faster than any other test of its kind, with targeted accuracy to match laboratory-based tests.

Key Topics Covered:

Chapter 1 Introduction

  • Study Goals and Objectives

  • Reasons for Doing This Study

  • Scope of Report

  • Information Sources

  • Methodology

  • Geographic Breakdown

  • Analyst's Credentials

  • Custom Research

  • Related Reports

Chapter 2 Summary and Highlights

  • Trends in Price/Performance

  • Market Ramp-Up in Equipment

  • Explosion in Uses

  • Pushing Molecular to the Patient

  • Evolving from Single-Test to Panels

Chapter 3 Market and Technology Background

  • Introduction

  • Evolution

  • History of PCR

  • 1950s-1960s

  • 1970s-1980s

  • 1990s-2017

  • Ultra-fast PCR Technologies for Point-of-Care Testing

  • Thermal Cycling Limits the Use of Conventional PCR at the POC

  • Approaches to Manage PCR Thermal Cycling

  • Novel Approaches for POC

  • Laser PCR: Expanding the Possibilities at the POC

  • Conclusions

  • New Approaches to Tackle Technical Challenges Correlated with Nucleic Acid-based POC Assays

  • Market Determinants

  • High Incidence of Infectious Diseases

  • Increasing Prevalence of COVID-19

  • Uses of POC PCR

  • Infectious Disease

  • Sexually Transmitted Disease

  • Other Uses

  • POC PCR Technology

  • Detection

  • Isothermic Amplification

  • Microfluidics

  • Regulatory Framework

Chapter 4 COVID-19 Impact Analysis

  • FDA's Contribution to COVID-19 Diagnostic Testing

  • Prioritizing of OTC and At-Home Testing Solutions

  • Synopsis of FDA-Associated Testing Milestones, Since May 2020

  • Competitive Landscape Specific to COVID-19 Impact Analysis

  • Developments in COVID-19 Testing

  • Meridian Introduces Novel Air-Dryable RT-qPCR Mix

  • FDA Allows Roche's Novel Diagnostic Test for Identifying MRSA Bacteria

  • Diagnostic Test for Combined Flu/SAR-CoV-2

Chapter 5 POC PCR Market Breakdown by Equipment

Chapter 6 POC PCR Market Breakdown by Kits

  • Infectious Diseases

  • Multi-analyte Panels

  • Single Analyte

  • Sexually Transmitted Diseases

  • Biomarkers

Chapter 7 POC PCR Market Breakdown by Region

  • North America

  • United States

  • Canada

  • Europe

  • Asia-Pacific

  • Rest of the World

  • Latin America

Chapter 8 Patent Review/New Developments

Chapter 9 Technology Issues

  • Emerging Diseases and POC PCR

  • Point-of-Care Testing: Not Just at The Patient Bedside

  • Quality Control of POC PCR

  • Company Strategies

Chapter 10 Industry Structure

  • Public Health

  • Clinical Diagnostics

  • Industrial

Chapter 11 Digital PCR Additional Information

  • Case Study: dPCR Offers More Absolute Results Over qPCR

  • Porter's Five Forces Model

  • Threat of New Entrants

  • Bargaining Power of Buyers

  • Bargaining Power of Suppliers

  • Threat of Substitutes

  • Competitive Rivalry Between Existing Players

  • Droplet Digital PCR

  • Applications of Digital PCR

  • Clinical

  • Research

  • Forensics

  • Industry Structure

Chapter 12 Company Profiles

  • Abbott Laboratories

  • Advanced Theranostics Inc.

  • Aquila Diagnostics Systems Inc.

  • Atlas Genetics

  • Bio-Rad Laboratories Inc.

  • Cepheid

  • Fluxergy

  • Qiagen N.V.

  • Roche Diagnostics

  • Visby Medical Inc.

For more information about this report visit https://www.researchandmarkets.com/r/rvnexw

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900